Sputnik V likely to offer two-year protection against coronavirus – developers

MOSCOW, December 12. /TASS/. Russia’s Sputnik V vaccine is likely to offer two-year-long protection against the novel coronavirus, said Alexander Gintsburg, the head of the vaccine’s developer, Gamaleya National Research Center for Epidemiology and Microbiology.

“So far, I can only make suggestions, because more experimental data is needed. Our vaccine was created on the platform also used for the Ebola vaccine. Experimental data received at that point demonstrate that a similar vaccine would offer protection for two years, maybe more,”  he told the Soloviev Live channel on YouTube.

According to the Russian scientist, Sputnik V is effective in 96% of cases. The remaining four percent of vaccinated persons will have a mild form of the disease with runny nose, cough and slight fever, but lungs won’t be affected.

Gintsburg explained the criticism of Russia’s Sputnik V vaccine by unfair market competition and political motives.

The other reason are political motives, Gintsburg continued.

Registered by Russia on August 11, Sputnik V became the world’s first coronavirus vaccine. The vaccine was developed by the Gamaleya National Research Center of Epidemiology and Microbiology. Its post-registration trials began in Moscow on September 7, with volunteers receiving the first vaccine on September 9. A total of 40,000 people are involved in the program, 10,000 of them received a placebo instead of the vaccine.

According to interim research results, the efficacy of the Sputnik V vaccine exceeds 95% on the 42nd day after the first dose, provided that a patient receives the second dose.

On December 2, Russian President ordered to organize a nationwide vaccination starting by the end of this week. As Prime Minister added, the inoculation should be completely voluntary and free of charge, with teachers, medics, and social workers receiving the vaccine first, while the regions can expand this list.

Read original article here.